Gerresheimer (GXI) 주식 개요
게레스하이머 AG는 자회사와 함께 독일 및 전 세계에서 의약품 포장, 약물 전달 장치 및 솔루션을 제조 및 판매합니다. 자세히 보기
GXI Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Gerresheimer AG 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €25.20 |
| 52주 최고가 | €66.50 |
| 52주 최저가 | €14.83 |
| 베타 | 0.33 |
| 1개월 변동 | 35.78% |
| 3개월 변동 | 0.32% |
| 1년 변동 | -58.65% |
| 3년 변동 | -74.46% |
| 5년 변동 | -72.05% |
| IPO 이후 변동 | -34.29% |
최근 뉴스 및 업데이트
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Recent updates
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Feb 10
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Nov 30GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
Nov 02Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
Sep 18Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Jul 31Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Jun 18Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
May 30Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
May 29Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
May 14Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Apr 24Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Apr 19It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Apr 11Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Mar 05Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Feb 25
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Jan 12Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
Dec 26Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
Oct 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Sep 29Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
Aug 31주주 수익률
| GXI | DE Life Sciences | DE 시장 | |
|---|---|---|---|
| 7D | 5.1% | 0.3% | 0.07% |
| 1Y | -58.7% | -19.5% | 1.1% |
수익률 대 산업: GXI은 지난 1년 동안 -19.5%의 수익을 기록한 German Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: GXI은 지난 1년 동안 1.1%를 기록한 German 시장보다 저조한 성과를 냈습니다.
주가 변동성
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 16.4% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.6% |
안정적인 주가: GXI의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.
시간에 따른 변동성: GXI의 주간 변동성은 지난 1년간 10%에서 16%로 증가했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1864 | 13,535 | Uwe Röehrhoff | www.gerresheimer.com |
게레스하이머 AG는 자회사와 함께 독일 및 전 세계에서 의약품 포장, 약물 전달 장치 및 솔루션을 제조 및 판매합니다. 이 회사는 세 개의 사업부로 운영됩니다: 플라스틱 및 장치, 1차 포장 유리, 첨단 기술 사업부입니다. 이 회사는 프리필드형 주사기, 플라스틱 및 유리 포장 솔루션, 바이알, 유리 카트리지 및 앰플, 병 및 용기, 유리병 및 항아리, 캡, 마개, 어플리케이터 및 액세서리, 약물 전달 프로그램의 개발, 산업화 및 계약 제조, 프로젝트 및 품질 관리, 흡입기, 주사/자동 주입기, 펜 주입기, 주입 시스템 및 흡입 평가, 자동 주입기 및 기타 서비스를 포함한 약물 전달 시스템 등을 제공합니다.
Gerresheimer AG 기초 지표 요약
| GXI 기초 통계 | |
|---|---|
| 시가총액 | €847.61m |
| 순이익 (TTM) | €23.35m |
| 매출 (TTM) | €2.25b |
37.3x
주가수익비율(P/E)0.4x
주가매출비율(P/S)GXI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| GXI 손익계산서 (TTM) | |
|---|---|
| 매출 | €2.25b |
| 매출원가 | €1.65b |
| 총이익 | €605.15m |
| 기타 비용 | €581.80m |
| 순이익 | €23.35m |
최근 보고된 실적
Aug 31, 2025
다음 실적 발표일
Jul 14, 2026
| 주당순이익(EPS) | 0.68 |
| 총이익률 | 26.89% |
| 순이익률 | 1.04% |
| 부채/자본 비율 | 155.5% |
GXI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.2%
현재 배당 수익률6%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/04 22:25 |
| 종가 | 2026/05/04 00:00 |
| 수익 | 2025/08/31 |
| 연간 수익 | 2024/11/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Gerresheimer AG는 35명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |